Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) - Related Studies

Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

This study has been completed.

Study NCT00000542. Last updated on April 22, 2008. Information provided by National Heart, Lung, and Blood Institute (NHLBI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Cardiovascular Diseases
		Coronary Disease
		Diabetes Mellitus
		Heart Diseases
		Hypercholesterolemia
		Hypertension
		Myocardial Infarction
		Myocardial Ischemia
		Heart Failure

2	Additional conditions recognized in this trial
		Infarction
		Ischemia

3	More general conditions related to this trial
		Dyslipidemias
		Endocrine System Diseases
		Glucose Metabolism Disorders
		Hyperlipidemias
		Lipid Metabolism Disorders
		Metabolic Diseases
		Necrosis
		Pathologic Processes
		Vascular Diseases

4	Interventions listed in this trial
		Inhibitors, ACE
		amlodipine
		lisinopril
		doxazosin
		chlorthalidone
		pravastatin
		diet, fat-restricted

5	More general drug interventions related to this trial
		Angiotensin-Converting Enzyme Inhibitors
		Anticholesteremic Agents
		Antihypertensive Agents
		Antilipemic Agents
		Antimetabolites
		Calcium Channel Blockers
		Cardiotonic Agents
		Cardiovascular Agents
		Diuretics
		Enzyme Inhibitors
		Hydroxymethylglutaryl-CoA Reductase Inhibitors
		Membrane Transport Modulators
		Molecular Mechanisms of Pharmacological Action
		Natriuretic Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Protease Inhibitors
		Protective Agents
		Sodium Chloride Symporter Inhibitors
		Therapeutic Uses
		Vasodilator Agents

6	Sponsors listed in this trial
		National Heart, Lung, and Blood Institute (NHLBI)